Why Partner with Us

Robust global networks

A truly global company, connecting over 30 countries

Multiple areas of opportunity

From co-developing drugs to out-licensing – collaboration is key

Legacy of results and delivery

Over 25 years of forwarding science at Dr. Reddy’s Biologics

Our Network of Partners

  • All
  • In-licensing
  • Out-licensing
  • Co-development
Alvotech
Healthcare Pharmaceuticals Limited
Coya Therapeutics

Processes Involved Toward Partnership

Please expect to go through the following processes on the way to successful deal closure. 

Write to us using the Enquiry Form below.

Non-Disclosure Agreement (NDA):
Business Case and Opportunity Assessment:
Term Sheet:
Due Diligence:
Licensing Agreement:
Supporting Agreements:
0/40
0/40
0/250

Our Network

Our News, Stories, and Insights

Comparing immunogenicity and safety
  • Publication
  • 21-12-2024

Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study

  • Publication
  • 05-11-2024

Efficacy and Safety of Rituximab Biosimilar (DRL_RI) Versus Mabthera in Low Tumor Burden Follicular Lymphoma: The Flinter Study

  • News
  • 23-09-2025

Dr Reddy’s receives positive CHMP opinion from EMA for AVT03, a proposed biosimilar of Prolia and Xgeva

  • News
  • 10-08-2025

Dr. Reddy’s Hematology Division has received the prestigious Stellar Research Award from the National Medical Forum – New Delhi, honouring excellence in medical research.

Bricks of Biologics, appreciates the contribution and celebrates our people who are the building blocks of Dr. Reddy's Biologics.

 

Bricks of biologics in general refers to bio-bricks as genetic building blocks which are DNA sequences that can be assembled to create complex biological systems.